epidermal growth factor receptor (EGFR)

On target clinical trial success bullseye score
Biotech

Cullinan plans approval push for NSCLC drug after ph. 2 win

Cullinan has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the data close to its chest for now.
James Waldron Jan 29, 2025 6:15am
graphic art of a right hand signing something

Avenue secure rare disease med while Allist lands cancer drug

Mar 2, 2023 11:00am